June 2018 in “The Journal of Sexual Medicine” Finasteride helps female-pattern hair loss.
March 2009 in “The Journal of Urology” Finasteride improves urinary symptoms and quality of life in BPH patients, especially with larger prostate size.
17 citations
,
August 2011 in “Current Medicinal Chemistry” New treatments for enlarged prostate are being developed, some of which may be more effective than current medications.
January 2002 in “映像情報メディア学会技術報告” Some prostate cancers have gene changes that may affect treatment with certain drugs.
26 citations
,
December 2023 in “Prostate International” Medications for BPH can have significant side effects, so understanding these risks is important for treatment decisions.
March 2016 in “The Journal of Urology” The discovery of 5α-reductase deficiency in guevedoces led to the development of important urologic medications.
35 citations
,
May 2002 in “Journal of the European Academy of Dermatology and Venereology” Chronic pelvic pain in men is common, but its cause is unknown and treatments are often ineffective.
3 citations
,
July 2022 in “BMC chemistry” The methods accurately measure finasteride and tadalafil in Entadfi™ capsules for quality control.
April 2024 in “The Journal of urology/The journal of urology” SRD5A2 methylation in blood can predict how well someone will respond to finasteride treatment.
15 citations
,
November 2015 in “Pharmacopsychiatry” α-Blockers and 5-ARIs for BPH can cause sexual dysfunction, including erectile and ejaculatory issues.
2 citations
,
August 2011 in “Cochrane Database of Systematic Reviews” November 2003 in “PubMed” March 2014 in “The Journal of Urology” Long-term treatment with finasteride or combined therapy worsens sexual function in men with urinary issues.
37 citations
,
May 2007 in “International Journal of Pharmaceutics” PPCM microspheres allow controlled finasteride release over 24 hours.
7 citations
,
January 2018 in “Reproduction” Inhibiting 5α-reductase increases progesterone levels in late pregnant mares.
18 citations
,
December 2016 in “European journal of pharmacology” A new compound slows cancer cell growth and causes cell death by blocking cell cycle progression and increasing cell-damaging molecules.
July 2024 in “Age and Ageing” Men taking dutasteride may have a higher risk of age-related macular degeneration.
October 2019 in “European heart journal” Androgen-deprivation therapies increase the risk of certain heart conditions, but testosterone treatment may help.
26 citations
,
August 2016 in “Translational Andrology and Urology” Treatments for urinary symptoms often cause ejaculatory problems.
30 citations
,
June 2021 in “British Journal of Dermatology” Mutations in the WNT10A gene can cause skin, hair, teeth, and other disorders, and may also affect other areas like kidney and cancer, with potential for targeted treatments.
45 citations
,
August 2010 in “Hormone Molecular Biology and Clinical Investigation” Type 3 5α-reductase is more common and finasteride and dutasteride strongly inhibit it.
June 2019 in “Reactions Weekly”
June 2025 in “International Journal of Nephrology and Renovascular Disease” PLA2R1 overexpression harms kidney cells by stopping their growth cycle.
January 2020 in “Química Nova” The PW91 method is best for calculating the basic physical and chemical properties of Finasteride, a drug used for prostate issues and hair loss.
August 2009 in “Australian Prescriber” Dutasteride is approved to help manage prostate enlargement.
June 2018 in “The Journal of Sexual Medicine” Low-intensity shock wave therapy is effective in treating erectile dysfunction in diabetic patients.
1 citations
,
January 2002 in “El Servicio de Difusión de la Creación Intelectual (National University of La Plata)” Finasteride effectively reduces prostate size in dogs with benign prostatic hyperplasia at a low, safe dose.
8 citations
,
May 2016 in “Indian Journal of Pharmacology” Finasteride and dutasteride can cause severe, lasting side effects.
PLX, a tomato extract mix, may help treat prostate issues like BPH.
November 2023 in “The Journal of Urology” The conclusion is that future trials should report specific details about the PRP composition to better understand its effects on urologic conditions.